At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 89 enrolled
Drug / intervention
ABT-493 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-493 and ABT-530 in Adult Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
In Brief
A Phase 2 clinical trial evaluating ABT-493, ABT-530, and 2 other interventions for Chronic Hepatitis C and 2 related conditions. Completed, enrolled 89 participants.
Detailed Summary
The purpose of this study is to evaluate the safety and antiviral effect of multiple doses of ABT-493 and ABT-530 in adults with genotype 1 HCV.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartNov 2013
First PostedNov 2013
Primary CompletionJun 2015
TodayJul 2026
First PostedNov 26, 2013
Enrollment StartNov 1, 2013
Primary CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 12.6 years ago
Interventions
ABT-493drug
Tablet
ABT-530drug
Tablet
ABT-450/r/ABT-267, ABT-333drug
Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
Ribavirin (RBV)drug
Tablet